E3A Healthcare 4th Anniversary: Momentum
On November 30, 2023, E3A Healthcare hosted a magnificent 4th anniversary event in Shenzhen, greeting shareholders, partners, and friends from around the globe to mark this significant accomplishment.
At the start of the event, Dr. Shawn, E3A Healthcare's founder & CEO, Dr. Dieter Trau, E3A Healthcare's Co-founder & Chief Scientific Officer, Professor in Bioengineering at the National University of Singapore, and Mr. Allen Xu, Managing Director of Sequoia Capital China, gave opening remarks. Their remarks highlighted E3A Healthcare's progress in the last four years and offered well-wishes for the future.
Welcoming remarks by Dr. Shawn, Founder & CEO of E3A Healthcare
Opening remarks by Dr. Dieter Trau, Co-Founder & Chief Scientific Officer of E3A Healthcare
Opening remarks by Mr. Allen Xu, Managing Director, Sequoia Capital China
In Dr. Shawn’s keynote speech, he provided a comprehensive overview of E3A Healthcare's past, present, and future. He emphasized the company's grand vision of revolutionizing maternal and child health management with convenient and reliable solutions. Dr. Shawn also candidly shared the challenges and setbacks faced by E3A Healthcare during its development, but highlighted how these obstacles have ultimately strengthened the team's resolve to move towards a brighter future.
Mr. Harry, Partner & CFO of E3A Healthcare, hosted the event
The event unveiled the latest product development roadmap and innovations from E3A Healthcare. Currently, E3A Healthcare offers products covering newborn and women’s healthcare, such as a fetal heart rate monitor for early pregnancy, a fetal monitor for late pregnancy, and a jaundice detector and blue light therapy device for newborn.
In addition, E3A Healthcare continuously develops various medical devices, such as non-invasive instruments for pelvic floor repair and menstrual pain relief, along with other innovative products. With consumers’ focus on health and quality of life steadily increasing in recent years, E3A Healthcare aims to capitalize on opportunities in the trillion-dollar consumer healthcare market. By expanding its medical-grade technologies and products to consumer-grade applications, E3A Healthcare seeks to offer a more universal and professional healthcare solution for newborns and women.
During the speech, Dr. Shawn also announced that E3A Healthcare has completed the PreA+ financing round led by Capital Asia Investments, and unveiled the delightful news of Series A financing.
Keynote speech, “E3A Healthcare’s Strategy for the future” by Dr. Shawn Li
In the near future, E3A Healthcare aims to promote healthy growth in newborns and improve the quality of life for women through continuous scientific and technological advancements. Moreover, we endeavor to assist every healthy family with a diverse product range and reliable services.
And then, Ms. Amy Zhang, Vice President of Quam Capital Limited, detailed the listing rules for 18A biotechnology companies on the Hong Kong Stock Exchange and shared the capital financing plans for E3A Healthcare. We'll remain attentive to capital path planning and actively explore the future development prospects of the capital market.
Keynote speech “Investment Outlook and Hong Kong 18A Listing Process for the Healthcare Industry”
by Amy Zhang
At the end of the event, E3A Healthcare also presented awards to the outstanding team members, thanked each team member for their hard work, and looked forward to creating a brighter future together.
E3A Healthcare will remain committed to innovation and developing superior solutions and products for families worldwide. As a medical technology company specializing in newborn and women's healthcare solutions, we firmly believe that E3A Healthcare will play an even bigger role in advancing the global cause of women's and newborn health in the future.
Group Photo
